₹16.45
(Market cap
₹1,245 Cr
Recently Viewed
Clear AllMarket cap
₹1,245 Cr
Revenue (TTM)
₹652 Cr
P/E Ratio
14.2
P/B Ratio
1.7
Div. Yield
0.3 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹88 Cr
ROE
13 %
ROCE
17.6 %
Industry P/E
29.85
EV/EBITDA
9.4
Debt to Equity
0
Book Value
₹371.6
EPS
₹43.9
Face value
10
Shares outstanding
20,029,728
CFO
₹565.63 Cr
EBITDA
₹745.62 Cr
Net Profit
₹566.94 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lincoln Pharma
| 28.5 | 4.1 | 37.3 | 4.9 | 16.7 | 19.1 | 14.8 |
|
BSE Healthcare
| 2.9 | 4.5 | 8.1 | 6.7 | 25.3 | 14.0 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Lincoln Pharma
| -43.5 | 22.8 | 71.4 | -0.8 | 47.3 | 18.7 | -9.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lincoln Pharma
|
622.0 | 1,245.0 | 651.9 | 87.8 | 13.1 | 12.7 | 14.2 | 1.7 |
| 2,807.2 | 35,057.6 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.6 | 7.6 | |
| 8,573.0 | 21,440.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 106.7 | 25.8 | |
| 1,761.1 | 13,403.9 | 2,089.5 | 622.0 | 31.3 | 20.4 | 21.8 | 4.0 | |
| 1,358.2 | 18,860.5 | 3,078.2 | 469.4 | 26.4 | 14.9 | 43.7 | 5.2 | |
| 2,047.5 | 32,880.0 | 4,193.0 | 753.8 | 22.7 | 20.8 | 43.6 | 8.2 | |
| 4,791.4 | 21,920.9 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.7 | 5.5 | |
| 5,175.5 | 8,592.8 | 1,348.5 | 293.5 | 28.1 | 50.7 | 29.3 | 12.3 | |
| 415.2 | 8,126.4 | 1,432.0 | 149.0 | 19.1 | 7.9 | 54.2 | 3.3 | |
| 1,098.6 | 10,116.4 | 4,725.6 | 528.7 | 14.9 | 20.7 | 19.8 | 3.4 |
No Review & Analysis are available.
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal,... corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. The company was incorporated in 1979 and is based in Ahmedabad, India. Read more
Incorporated
1995
Chairman
Kishor M Shah
Managing Director
Mahendra G Patel
Headquarters
Ahmedabad, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Lincoln Pharmaceuticals Ltd is ₹622.00 (NSE) and ₹621.55 (BSE) as of 27-Apr-2026 IST. Lincoln Pharmaceuticals Ltd has given a return of 16.72% in the last 3 years.
The P/E ratio of Lincoln Pharmaceuticals Ltd is 14.17 times as on 27-Apr-2026, a 53 discount to its peers’ median range of 29.85 times.
The P/B ratio of Lincoln Pharmaceuticals Ltd is 1.67 times as on 27-Apr-2026, a 64 discount to its peers’ median range of 4.60 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
13.42
|
1.64
|
|
2024
|
12.57
|
1.98
|
|
2023
|
9.31
|
1.35
|
|
2022
|
8.98
|
1.44
|
|
2021
|
7.23
|
1.23
|
The 52-week high and low of Lincoln Pharmaceuticals Ltd are Rs 677.00 and Rs 440.00 as of 27-Apr-2026.
Lincoln Pharmaceuticals Ltd has a market capitalisation of ₹ 1,245 Cr as on 27-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Lincoln Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.